Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Ovid Therapeutics (OVID) over the last 5 years, with Q3 2025 value amounting to $5.0 million.

  • Ovid Therapeutics' Short-term Investments fell 8953.35% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 8953.35%. This contributed to the annual value of $26.8 million for FY2024, which is 6601.94% down from last year.
  • As of Q3 2025, Ovid Therapeutics' Short-term Investments stood at $5.0 million, which was down 8953.35% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Short-term Investments ranged from a high of $84.1 million in Q4 2022 and a low of $5.0 million during Q3 2025
  • For the 4-year period, Ovid Therapeutics' Short-term Investments averaged around $46.4 million, with its median value being $47.5 million (2024).
  • As far as peak fluctuations go, Ovid Therapeutics' Short-term Investments surged by 8992.42% in 2024, and later plummeted by 8953.35% in 2025.
  • Over the past 4 years, Ovid Therapeutics' Short-term Investments (Quarter) stood at $84.1 million in 2022, then decreased by 6.35% to $78.8 million in 2023, then plummeted by 66.02% to $26.8 million in 2024, then tumbled by 81.36% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $9.9 million for Q2 2025, and $21.9 million during Q1 2025.